Provided by: Mycenax Biotech Inc. Finacial year: Yearly Unit: NT\$ thousand

Accounting Title	2016/12/31	2015/12/31
Balance Sheet		
Current assets		
Total cash and cash equivalents	309,771	305,61
Total Current investments in debt instrument without active market	455,399	859,86
Notes receivable due from related parties, net	0	7
Accounts receivable, net	23,328	18,57
Accounts receivable due from related parties, net	24,472	
Other receivables, net	2,838	2,89
Total current tax assets	1,907	4,03
Total inventories	50,395	22,62
Total prepayments	19,989	21,57
Total other current assets	48,402	9,32
Total current assets	936,501	1,244,58
Non-current assets		
Non-current financial assets at cost, net	20,000	
Total Non-current investments in debt instrument without active market	30,000	30,00
Total property, plant and equipment	315,000	199,87
Total intangible assets	2,342	58
Deferred tax assets	39,599	40,17
Total other non-current assets	45,906	3,17
Total non-current assets	452,847	273,80
Total assets	1,389,348	1,518,38
Current liabilities		
Total accounts payable	22,069	19,61
Total accounts payable to related parties	0	4
Total other payables	42,658	30,36
Other payables to related parties	6	·
Total other current liabilities	5,728	11,61
Total current liabilities	70,461	61,63
Non-current liabilities		·
Total deferred tax liabilities	473	79
Total other non-current liabilities	2,271	1,73
Total non-current liabilities	2,744	2,53
Total liabilities	73,205	64,17
Share capital		
Ordinary share	1,120,005	1,115,99
Advance receipts for share capital	807	2,21
Total share capital	1,120,812	1,118,20
Capital surplus		
Total capital surplus, additional paid-in capital	621,104	614,63
Capital surplus, treasury share transactions	2,812	2,81
Capital surplus, employee share options	15,695	3,87
Total capital surplus	639,611	621,31
Retained earnings		·
Total unappropriated retained earnings (accumulated deficit)	-356,669	-197,69
Total retained earnings	-356,669	-197,69
Other equity interest		•
Total other equity, others	0	
Total other equity interest	0	
Treasury shares	-87,611	-87,61
Total equity	1,316,143	1,454,21
Total liabilities and equity	1,389,348	1,518,38
Number of share capital awaiting retirement	0	,,
Equivalent issue shares of advance receipts for ordinary share	44,000	116,00
Number of shares in entity held by entity and by its subsidiaries	2,200,000	2,200,00

Provided by: Mycenax Biotech Inc. Finacial year: Yearly Unit: NT\$ thousand

Unit: NT\$ thousand		_			
Accounting Title	2016/4th	2015/4th			
Income Statement					
Total operating revenue	200,606	134,857			
Total operating costs	160,359	97,508			
Gross profit (loss) from operations	40,247	37,349			
Gross profit (loss) from operations	40,247	37,349			
Operating expenses					
Total selling expenses	9,722	3,664			
Total administrative expenses	31,155	29,788			
Total research and development expenses	217,775	144,966			
Total operating expenses	258,652	178,418			
Net operating income (loss)	-218,405	-141,069			
Non-operating income and expenses					
Total other income	63,259	29,867			
Other gains and losses, net	-2,989	930			
Total non-operating income and expenses	60,270	30,797			
Profit (loss) from continuing operations before tax	-158,135	-110,272			
Total tax expense (income)	350	617			
Profit (loss) from continuing operations	-158,485	-110,889			
Profit (loss)	-158,485	-110,889			
Other comprehensive income					
Components of other comprehensive income that will not be reclassified to profit or loss					
Gains (losses) on remeasurements of defined benefit plans	-588	1,360			
Income tax related to components of other comprehensive income that will not be reclassified to profit or loss	-99	231			
Other comprehensive income, net	-489	1,129			
Total comprehensive income -158					
Basic earnings per share					
Total basic earnings per share	-1.45	-1.01			

Provided by: Mycenax Biotech Inc. Finacial year: Yearly Unit: NT\$ thousand

Unit: NT\$ thousand	2010111	
Accounting Title	2016/4th	2015/4th
Statements of Cash Flows		
Cash flows from (used in) operating activities, indirect method		
Profit (loss) from continuing operations before tax	-158,135	-110,272
Profit (loss) before tax	-158,135	-110,272
Depreciation expense	41,375	34,209
Amortization expense	1,044	1,282
Provision (reversal of provision) for bad debt expense	4	C
Interest income	-8,075	-13,952
Share-based payments	14,686	478
Loss (gain) on disposal of property, plan and equipment	205	(
Impairment loss on non-financial assets	610	74
Total adjustments to reconcile profit (loss)	49,849	22,091
Decrease (increase) in notes receivable due from related parties	71	-71
Decrease (increase) in accounts receivable	-4,762	21,583
Decrease (increase) in accounts receivable due from related parties	-24,472	4,927
Decrease (increase) in other receivable	-231	5,213
Decrease (increase) in inventories	-28,378	-7,736
Decrease (increase) in prepayments	1,587	-9,009
Decrease (increase) in other current assets	-465	648
Total changes in operating assets	-56,650	15,555
Increase (decrease) in accounts payable	2,450	8,186
Increase (decrease) in accounts payable to related parties	-40	17
Increase (decrease) in other payable	7,977	4,478
Increase (decrease) in other payable to related parties	6	C
Increase (decrease) in other current liabilities	-5,890	-3,795
Increase (decrease) in net defined benefit liability	-54	131
Total changes in operating liabilities	4,449	9,017
Total changes in operating assets and liabilities	-52,201	24,572
Total adjustments	-2,352	46,663
Cash inflow (outflow) generated from operations	-160,487	-63,609
Income taxes refund (paid)	2,131	-1,310
Net cash flows from (used in) operating activities	-158,356	-64,919
Cash flows from (used in) investing activities	100,000	0.,0.0
Acquisition of investments in debt instrument without active market	-250,517	-1,035,889
Proceeds from disposal of investments in debt instrument without active market	654,985	1,301,771
Acquisition of financial assets at cost	-20,000	.,001,111
Acquisition of property, plant and equipment	-107,471	-63,928
Increase in refundable deposits	0	-1,348
Decrease in refundable deposits	439	.,
Acquisition of intangible assets	-2,522	
Increase in other financial assets	-51,207	-9,069
Decrease in other financial assets	12,593	0,000
Increase in prepayments for business facilities	-88,369	-153
Interest received	8,360	13,910
Net cash flows from (used in) investing activities	156,291	205,294
Cash flows from (used in) financing activities	100,231	200,20
Exercise of employee share options	6,217	14,001
Payments to acquire treasury shares	0,217	-87,611
Net cash flows from (used in) financing activities	6,217	-73,610
Effect of exchange rate changes on cash and cash equivalents	0,217	-70,010
Net increase (decrease) in cash and cash equivalents	4,152	66,765
Cash and cash equivalents at beginning of period	305,619	238,854
Cash and cash equivalents at beginning of period Cash and cash equivalents at end of period	309,771	305,619
Cash and cash equivalents at end of period Cash and cash equivalents reported in the statement of financial position	309,771	305,619
Other items qualifying for cash and cash equivalents under the definition of IAS 7	309,771	303,018

Financial Statement - Statements of Changes in Stockholders' Equity

Provided by: Mycenax Biotech Inc. Finacial year: Yearly Unit: NT\$ thousand

2016/12/31 Statement of Stockholders' Equity

Accounting Title		ceipts for share capital Total	share capital C	apital surplus Unappropriated retained earnings (accumula	ated deficit) Total reta	ained earnings Exchange differences on translation of foreign financial staten	nents Gains (losses) from investments in equity instruments measured at fair value through other comprehensive	income Unrealized gains (losses) on available-for-sale financial as	sets Gains (losses) on effective portion of cash flow her	edges Gains (losses) on effective portion of hedges of net investments in foreign operation	ns Change in fair value of financial liability attributable to change in credit risk of liab	ility Gains (losses) on remeasurements of defined bene	fit Revaluation surplus Equity related to non-current assets classified as he	d for sale Others	s Total other equity interes	st Treasury shares Total equity
Equity at beginning of period Effects of retrospective application and retrospective restatement Retrospective adjustment of equity attributable to former owner due to reorganization of entities under common contro Equity at beginning of period after adjustments	1,115,990	2,211	1,118,201	621,319	-197,695	-197,695	0	0	0	0	0	0	0 0	0 0	0 (0 -87,611 1,454,214
Effects of retrospective application and retrospective restatement	0	0	0	0	0	0	0	0	0	0	0	0	0 0	0 0	0 (0 0 0
Retrospective adjustment of equity attributable to former owner due to reorganization of entities under common control	0 او	0	0	0	0	0	o	0	0	0	0	0	0 0	0 0	0 (0 0 0
Equity at beginning of period after adjustments	1,115,990	2,211	1,118,201	621,319	-197,695	-197,695	0	0	0	0	0	0	0 0	0 0	0 (0 -87,611 1,454,214
Profit (loss)	0	0	0	0	-158,485	-158,485	o	0	0	0	0	0	0 0	0 0	0 (0 -158,485
Other comprehensive income	0	0	0	0	-489	-489	o	0	0	0	0	0	0 0	0 0	0 (0 0 -489
Total comprehensive income	0	0	0	0	-158,974	-158,974	o	0	0	0	0	0	0 0	0 0	0 (0 -158,974
Share-based payments	4,015	-1,404	2,611	18,292	0	0	o	0	0	0	0	0	0 0	0 0	0	0 0 20,903
Total increase (decrease) in equity	4,015	-1,404	2,611	18,292	-158,974	-158,974	o	0	0	0	0	0	0 0	0 0	0 (0 -138,071
Equity at end of period	1,120,005	807	1,120,812	639,611	-356,669	-356,669	0	0	0	0	0	0	0 0	0 0	0 (0 -87,611 1,316,143
Accounting Title		ceipts for share capital Total	share capital C	apital surplus Unappropriated retained earnings (accumula	ated deficit) Total reta	ained earnings Exchange differences on translation of foreign financial staten	nents Gains (losses) from investments in equity instruments measured at fair value through other comprehensive	Unit: NT\$ thousand income Unrealized gains (losses) on available-for-sale financial as	sets Gains (losses) on effective portion of cash flow hed	edges Gains (losses) on effective portion of hedges of net investments in foreign operation	ns Change in fair value of financial liability attributable to change in credit risk of liab	ility Gains (losses) on remeasurements of defined bene	fit Revaluation surplus Equity related to non-current assets classified as he	d for sale Others	s Total other equity interes	st Treasury shares Total equity
Equity at beginning of period	1.109.260	1.660	1.110.920	614.121	-87.935	-87.935	0	0	0	0	0	0	0 0	0 0	0 0	0 0 1.637.106
Effects of retrospective application and retrospective restatement	0	0	0	0	0	0	ol .	0	0	0	0	0	0 0	0 0	0 (0 0 0
Equity at beginning of period Effects of retrospective application and retrospective restatement Retrospective adjustment of equity attributable to former owner due to reorganization of entities under common contro	0	0	0	0	0	0	0	0	0	0	0	0	0 0	0 0	0 (0 0 0
Equity at beginning of period after adjustments	1,109,260	1,660	1,110,920	614,121	-87,935	-87,935	0	0	0	0	0	0	0 0	0 0	0 (0 1,637,106
Profit (loss)	0	0	0	0	-110,889	-110,889	0	0	0	0	0	0	0 0	0 0	0 (0 -110,889
Other comprehensive income	0	0	0	0	1,129	1,129	o	0	0	0	0	0	0 0	0 0	0 (0 0 1,129
Total comprehensive income Purchase of treasury share	0	0	0	0	-109,760	-109,760	0	0	0	0	0	0	0 0	0 0	0 (0 -109,760
Purchase of treasury share	0	0	0	0	0	0	0	0	0	0	0	0	0 0	0 0	0	0 -87,611 -87,611
Share-based payments	6,730	551	7,281	7,198	0	0	0	0	0	0	0	0	0 0	0 0	0 (0 0 14,479
Total increase (decrease) in equity	6.730	551	7 281	7 108	100.760	-109 760	nl	0	0	0		٥		0 0	0	0 -87 611 -182 802
	0,700	001	7,201	7,150	-109,700	-105,700	9	9	0	0	0	9	0	0 0	Ŭ (-07,011 -102,002